Eylea approved in Japan for new CRVO indication
This article was originally published in Scrip
Following a positive opinion in October, Japan has granted a formal final approval to Bayer's VEGF inhibitor Eylea (aflibercept) for the additional indication of macular edema secondary to central retinal vein occlusion (CRVO).
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.